Secondary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-LenalidomideDexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

被引：1
|
作者：
Lim, Sueh-li [1 ,2 ]
Reynolds, John [3 ,4 ]
Quach, Hang [5 ,6 ]
Hutchinson, Anna [7 ]
Kerridge, Ian H. [8 ,9 ]
Estell, Jane [10 ]
Wallington-Gates, Craig [11 ,12 ]
Kalff, Anna [1 ,2 ]
Yuen, Flora [13 ]
Spencer, Andrew [14 ]
机构：
[1] Monash Univ, Australian Ctr Blood Dis, Melbourne, Vic, Australia
[2] Alfred Hlth, Malignant Haematol & Stem Cell Transplantat Serv, Melbourne, Vic, Australia
[3] Monash Univ, Dept Haematol, Alfred Hosp, Melbourne, Vic, Australia
[4] Monash Univ, Fac Med Nursing & Hlth Sci, Melbourne, Vic, Australia
[5] Univ Melbourne, St Vincents Hosp, Melbourne, Vic, Australia
[6] St Vincents Hosp, Clin Haematol Serv, Melbourne, Vic, Australia
[7] Royal Hobart Hosp, Dept Haematol, Hobart, Tas, Australia
[8] Univ Sydney, Sydney, NSW, Australia
[9] Royal North Shore Hosp, Sydney, NSW, Australia
[10] Concord Hosp, Concord Canc Ctr, Haematol Dept, Concord, Australia
[11] Univ South Australia, Flinders Univ, Ctr Canc Biol, Flinders Med Ctr,Coll Med & Publ Hlth, Bedford Pk, SA, Australia
[12] SA Pathol, Adelaide, SA, Australia
[13] Monash Univ, Malignant Haematol & Stem Cell Transplantat, Melbourne, Vic, Australia
[14] Alfred Hlth Monash Univ, Malignant Haematol & Stem Cell Transplantat Serv, Melbourne, Vic, Australia
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-170697
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
653
引用
收藏
页码：10174 / 10176
页数：3
相关论文
共 9 条
  • [1] Preliminary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-LenalidomideDexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy
    Lim, Sueh-li
    Reynolds, John
    Quach, Hang
    Hutchinson, Anna
    Kerridge, Ian H.
    Estell, Jane
    Janowski, Wojt
    Wallington-Beddoe, Craig Thomas
    Kalff, Anna
    Yuen, Flora
    Spencer, Andrew
    BLOOD, 2021, 138
  • [2] Response adaptive salvage treatment with daratumumab-lenalidomide-dexamethasone for newly diagnosed transplant-eligible multiple myeloma patients failing front-line bortezomib-based induction therapy-ALLG MM21
    Lim, S.
    Reynolds, J.
    Quach, H.
    Hutchinson, A.
    Kerridge, I.
    Janowski, W.
    Bergin, K.
    Spencer, A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (03) : 900 - 914
  • [3] Preliminary Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) MM17 Trial: Response Adaptive Salvage Treatment with Carfilzomib-Thalidomide-Dexamethasone (KTd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy
    Spencer, Andrew
    Quach, Hang
    Horvath, Noemi
    Kerridge, Ian H.
    Yuen, Flora
    Lee, Edwin Sze-Hung
    Morris, Edward S.
    Kalff, Anna
    Bergin, Krystal
    Sirdesai, Shreerang
    Gorniak, Malgorzata
    Mithraprabhu, Sridurga
    Khong, Tiffany
    Reynolds, John
    BLOOD, 2018, 132
  • [4] Response Adaptive Salvage Treatment with Carfilzomib-ThalidomideDexamethasone for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line BortezomibBased Induction Therapy - Final Analysis from the Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial
    Turner, Rose
    Quach, Hang
    Horvath, Noemi
    Kerridge, Ian H.
    Yuen, Flora
    Lee, Edwin Sze-Hung
    Morris, Edward S.
    Kalff, Anna
    Bergin, Krystal
    Sridesai, Shreerang
    Gorniak, Malgorzata
    Mithraprabhu, Sridurga
    Khong, Tiffany
    Reynolds, John
    Spencer, Andrew
    BLOOD, 2021, 138
  • [5] Optimizing the Alcyone Trial: Efficacy of Daratumumab And Bortezomib Maintenance in Non-Transplant Eligible Newly Diagnosed Multiple Myeloma Patients Post Dara-Vmp Induction, 1 Year Analysis
    Tamariz-Amador, Luis Esteban
    Puertas, Borja
    Hernandez, Miguel
    Garcia, Alfonso
    Jesus Blanchard, Maria
    Ramirez-Payer, Angel
    Lerma, Ana
    Escalante, Fernando
    Cobo-Rodriguez, Maria Teresa
    Barez-Garcia, Abelardo
    Gonzalez-Perez, Marta
    De Soto, Teresa
    Suarez-Cabrera, Alexia
    Martinez-Castro, Margarita
    Sancho Val, Luis Ignacio
    Dios Loureiro, Ana
    Yus Cebrian, Flor
    Anguita, Magdalena
    Alonso, Arancha
    Gimenez Mesa, Eugenio
    Angel Mendez, Jose
    Jose Lahuerta, Juan
    Blade, Joan
    San-Miguel, Jesus
    Mateos Manteca, Maria-Victoria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S246 - S247
  • [6] Circular RNA_0003489 reflects unfavorable treatment response and shortened survival in newly diagnosed multiple myeloma patients who receive bortezomib-based induction therapy
    Song, Senhua
    Xie, Junjie
    Xu, Biao
    Ran, Qijie
    HEMATOLOGY, 2024, 29 (01)
  • [7] High-dose melphalan with bortezomib as conditioning regimen for autologous stem cell transplant in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy
    Huang, Wenrong
    Li, Jian
    Li, Honghua
    Kang, Wenying
    Bo, Jian
    Zhao, Yu
    Gao, Chunji
    Zhou, Daobin
    Yu, Li
    LEUKEMIA & LYMPHOMA, 2012, 53 (12) : 2507 - 2510
  • [8] Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies
    Callander, Natalie
    Silbermann, Rebecca
    Kaufman, Jonathan L.
    Godby, Kelly N.
    Laubach, Jacob P.
    Schmidt, Timothy Martin
    Sborov, Douglas W.
    Medvedova, Eva
    Reeves, Brandi
    Dhakal, Binod
    Rodriguez, Cesar
    Chhabra, Saurabh
    Chari, Ajai
    Bal, Susan
    Anderson, Larry D., Jr.
    Dholaria, Bhagirathbhai
    Nathwani, Nitya
    Hari, Parameswaran
    Shah, Nina
    Bumma, Naresh
    Holstein, Sarah A.
    Costello, Caitlin
    Jakubowiak, Andrzej
    Wildes, Tanya M.
    Orlowski, Robert Z.
    Shain, Ken H.
    Cowan, Andrew J.
    Pei, Huiling
    Cortoos, Annelore
    Patel, Sharmila
    Lin, Thomas S.
    Giri, Smith
    Costa, Luciano J.
    Richardson, Paul G.
    Usmani, Saad
    Voorhees, Peter M.
    BLOOD, 2022, 140 : 10144 - 10147
  • [9] In-Class Transition (iCT) from Parenteral Bortezomib-Based Induction to All-Oral Ixazomib-Lenalidomide-Dexamethasone in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma (NDMM): Updated Subgroup Analysis from the Community-Based US MM-6 Study
    Girnius, Saulius K.
    Richter, Joshua
    Lyons, Roger
    Bogard, Kimberly
    Manda, Sudhir
    Birhiray, Ruemu E.
    Yimer, Habte A.
    Tran, Kim
    Kambhampati, Suman
    Arora, Jyoti
    Noga, Stephen J.
    Rifkin, Robert M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S501 - S501
1